News
 

The negative impact of smoking on MS is well established, however, there is much less evidence on whether smoking cessation is beneficial for progression in MS.

Milk intake has been associated with risk of neurodegenerative diseases in observational studies. Nevertheless, whether the association is causal remains unknown. In a new study published in Nutrients the authors adopted Mendelian randomization design to evaluate the potential causal association between milk intake and common neurodegenerative...

Statins are more widely used not only for the primary and secondary prevention of cardiovascular disease by blocking cholesterol biosynthesis but also for the potential neuroprotective agents during neurological disorders due to their pleiotropic effects.

Since the coronavirus disease 2019 (COVID-19) has risen, several risk factors have been identified, predicting a worse outcome. It has been speculated that patients with Multiple sclerosis (MS) have an increased risk for a severe course of COVID-19 due to a suspected higher vulnerability. Therefore, in this new study the authors aimed to analyze...

Mediotemporal volume mediated the association between MeDi and memory (40% indirect mediation).

There is no safe amount of alcohol consumption for the brain; even moderate drinking adversely affects brain structure and function, according a British study of more 25,000 adults.

Recently, increasing attention has been paid to the effects of air pollutants on autoimmune diseases.

To evaluate the impact of the Coronavirus disease of 2019 (COVID‐19) pandemic on patients with migraine a study was designed and recently published: Haghdoost, F., Carcel, C., Chandrasekhar, D. et al. The impact of Coronavirus disease 2019 (COVID‐19) pandemic on migraine disorder. J Neurol (2021). https://doi.org/10.1007/s00415-021-10590-x

Autologous hematopoietic stem cell transplantation (aHSCT) is increasingly recognized as a potential therapy for patients with highly active multiple sclerosis (MS). This study (doi:10.1002/acn3.51366 ) aims to assess outcome differences in disease activity in MS patients treated either with aHSCT or alemtuzumab.

A minimally invasive blood test along with artificial intelligence (AI) may flag early-stage Alzheimer's disease (AD), raising the prospect of early intervention when effective treatments become available.